UNSPSC 51312506: Clobenzepam hydrochloride

This classification denotes a histamine-1 receptor antagonist C17H18ClN3O.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 618Q2FLB9R, chemically known as 2-(2-chloro-6-oxo-11h-benzo(b)(1,4)benzodiazepin-5-yl)ethyl-dimethyl-ammonium chloride, but more generally known as clobenzepam hydrochloride, which bears US NIH Compound Identifier 17646. Most nations, for tariff and trade purposes, schedule clobenzepam hydrochloride under HS 29339940 and SITC 51577.

As of Q4 2014, CLOBENZEPAM HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CN(C)CCN1C2CCC(CC2NC3CCCCC3C1=O)CL.CL.

UNSPSC 51312506 Clobenzepam hydrochloride is a Commodity code that in practice captures pharmaceutical procurement by state and local health agencies, though recent state and local solicitations tagged to this code address a broader pharmaceutical supply portfolio—including naloxone, generic multi-source pharmaceuticals, and over-the-counter products—rather than clobenzepam specifically. State and local governments use this code family to procure controlled and non-controlled medications, drug deactivation systems, and pharmaceutical distribution services through health departments, county health systems, cooperative purchasing alliances, and state health and human services agencies. The issuing bodies soliciting under the code span county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS Commission), and multi-state cooperative purchasing vehicles (Minnesota Multistate Cooperative Purchasing Alliance, which serves state and local members across participating jurisdictions including Oregon). Scope varies from single-product, single-jurisdiction procurements to broad multi-award frameworks serving dozens of government entities across multiple states.

Recent activity centers in Florida, Texas, and Minnesota. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through quarterly deliveries, with a response deadline of July 26, 2023 (note: deadline date appears inconsistent with post date in source data), requiring E-Verify compliance and fixed-fee pricing on a two-year initial term with one-year renewal option. Texas HHS Commission released Request for Information HHS0017013 on April 3, 2026, gathering vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program targeting direct contracting outside traditional pharmacy benefit managers and wholesalers. Minnesota Department of Administration's Office of State Procurement, administering MMCAP, issued RFP S1070000015802 on January 20, 2026, with response deadline March 26, 2026, to establish multiple contracts for generic pharmaceuticals and OTC products distributed through three authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, Morris & Dickson Co.), requiring cGMP certification, Drug Supply Chain Security Act compliance, and pricing competitiveness weighted at 75 percent of evaluation criteria, with contract effectiveness July 1, 2026.